Merck & Co hit by FDA’s rejection of new combo cholesterol drug
Merck & Co’s bid to revitalise its cholesterol portfolio has been dealt a blow as US regulators rejected the firm’s new combination treatment MK-0524A.
Read MoreAuthor: Kevin Grogan
Shire posts strong revenue growth, shrugs off Vyvanse fears
Shares in Shire have suffered a blip after the UK drugmaker suggested that 2008 sales of Vyvanse, the follow-up to its attention deficit hyperactivity disorder drug Adderall XR will be at the lower-end of a previous forecast.
Read MoreThailand disappointed to be on USTR watchlist yet again
The Thai government has expressed disappointment at finding itself once again on the USA’s ‘priority watch list,’ a ranking of serial violators of intellectual property, a decision which reflects the country’s policy of compulsory licensing for certain drugs.
Read MoreSkyePharma signs up Japan’s Kyorin as Flutiform partner
SkyePharma has been celebrating the signing of a licensing deal with Japan’s Kyorin Pharmaceutical Co for the UK firm’s flagship asthma combination drug Flutiform
Read MoreGSK buys anti-aging enzyme expert Sirtris for $720 million
GlaxoSmithKline has once again hit the acquisition trail and snapped up Sirtris Pharmaceuticals of the USA for $720 million, or $22.50 per share, a cash deal that represents a massive 84% premium on the latter’s stock price last night.
Read More- Atsena gains EMA orphan status for two gene therapies
- J&J reports major survival gains with dual‑target myeloma regimen
- OrbusNeich begins Japanese trial for drug‑coated balloon
- Nezglyal receives positive CHMP opinion supporting treatment access for boys with cALD
- Novogene Europe expands single‑cell sequencing capability in Cambridge
